And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal for weekend daydreams. Our agenda looks to be rather modest. We hope to catch up on some reading, manicure the Pharmalot campus grounds and play a canine version of rugby with our official mascot, who is quite a competitor. If time permits, we may also have a listening party. And what about you? This is a fine time to stroll among apple orchards or take a drive in the country. You could winterize your castle. Or boost the economy by purchasing a few sweaters. Well, whatever you do, have a grand time. But be safe Enjoy, and see you soon…
In a highly unusual move, the Centers for Disease Control and Prevention director Rochelle Walensky overruled a recommendation by an agency advisory panel that had refused to endorse booster shots of the Pfizer (PFE) -BioNTech (BNTX) Covid-19 vaccine for frontline workers, The New York Times tells us. The CDC panel recommended boosters for a wide range of Americans, including tens of millions of older adults and younger people at high risk for the disease, but excluded health care workers, teachers and others whose jobs put them at risk.
Amid mounting concerns over the U.S. pharmaceutical supply chain, a Department of Defense watchdog found an overreliance on foreign suppliers that could harm national security, but the Pentagon failed to assess the risks of shortages or develop strategies to mitigate disruptions, STAT reports. Among the shortcomings, the Defense Department did not aggregate and analyze the origins of finished medicines or active ingredients to determine the reliance on foreign suppliers.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect